The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
847
June 28, 1991
View Complete Issue         Table of Contents 2019 
Ondansentron To Prevent Vomiting After Cancer Chemotherapy
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ondansentron To Prevent Vomiting After Cancer Chemotherapy
June 28, 1991 (Issue: 847)
Ondansetron (on dan' se tron; Zofran - Glaxo), a serotonin (5-hydroxytryptamine) antagonist, was recently marketed in the USA for intravenous use to prevent nausea and vomiting due to cancer chemotherapy. An oral formulation is available in many ...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Ondansentron To Prevent Vomiting After Cancer Chemotherapy
Article code: 847b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.